Roivant Sciences price target lowered to $12 from $13 at BofA [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
In This Article ROIV IMVT BofA lowered the firm's price target on Roivant Sciences ( ROIV ) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call was “relatively uneventful” besides an announcement for initiating a Phase 2 trial for brepocitinib in cutaneous sarcoidosis, the analyst tells investors. The firm continues like the opportunity sets for IMVT -1402, but sees the rest of Roivant's (ROIV) pipeline as relatively early, says the analyst, who views Roivant and Immunovant (IMVT) as “tightly linked to 2025 pipeline updates” for first-generation FcRn drug batoclimab given that Roivant now owns 57% of Immunovant. Maximize Your Portfolio with Data Driven Insights: Leverage the power of TipRanks' Smart Score , a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio Published first on TheFly –
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor DayGlobeNewswire
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 144/A
- 12/15/25 - Form 144
- ROIV's page on the SEC website